Tres Uramigas shared on X:
“Sure! Here’s the post without the usernames:
AMBASSADOR: Phase III Ca Urothelial with muscle invasion post-cystectomy pembrolizumab 1 vs observation in New England Journal of Medicine, Andrea Apolo, Petros Grivas.
- Disease-Free Survival (DFS) benefit
- Independent of PD-L1 and nodal status
- Metastatic recurrences frequency in the control arm.”
Source: Tres Uramigas/X
